Compare BioNano Genomics Inc (BNGO) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Gold Fields Limited — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Gold Fields Limited trades at $33.02 (market cap $29.97B). The key difference: Gold Fields Limited is far larger — about 2270.5× BioNano Genomics Inc's market cap, and Gold Fields Limited pays a 6.96% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GFI | |
|---|---|---|
Market Cap | $13.20M | $29.97B |
Sector | Health | Basic Materials |
52-Week High | $4.92 | $61.52 |
52-Week Low | $1.09 | $23.95 |
Enterprise Value | $15.81M | $31.41B |
Dividend Yield | — | 6.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Gold Fields (GFI) trades at $33.53, down 1.79% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 8.51, net income margin of 40.76%, and robust ROE of 52.33%. Recent earnings were mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and revenue growth accelerated to $8.8B. Analyst consensus is a Buy with a $52.75 price target, though recent news highlights operational cost pressures.
The outlook for GFI is positive based on valuation and profitability, but near-term risks include cost inflation and gold price volatility. The stock offers value with upside to analyst targets, supported by strong cash generation and a shareholder-friendly dividend policy. Key risks are execution at mines and macroeconomic factors affecting gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
